Neuropeptide Compounds · Checked
DSIP
Every price, divided down to the milligram.
Vendors sell this compound in different vial sizes at different prices, which makes sticker prices useless for comparison. So we divide every listing by its stated peptide content and rank what comes out.
Vendors pay us a commission when you buy through our links. It never changes the order — rows are sorted by measured price per mg, and every flag is computed from the data shown. Read the full disclosure
Ranked by $ per mg
Sprays listed after the vials, unrankedHow this page is funded: vendors listed here pay us a commission when you buy through our links. Commissions never change the ranking — rows are ordered by measured price per mg, and flags are computed from the data on this page. Sponsored placements, if any, are always labeled.
On this page
How to read these rows
Verify the COA
A certificate of analysis should come from an independent lab, reference the exact batch number on the label, and be recent. Vendor-issued documents without a named third-party lab carry less weight — the COA row links to what each vendor publishes.
Match the format
Lyophilized vials and sprays are different products with different concentrations. That is why sprays sit outside the $/mg ranking — compare vials to vials, sprays to sprays.
Count the total cost
Shipping fees, free-shipping thresholds and active discount codes can flip which vendor is actually cheapest for your order size. The $/mg figure is the baseline; the shipping and code details finish the math.
How we rank
Rows are ordered by price per mg: listed price divided by stated peptide content, excluding shipping and codes, so every vial competes on the same axis. Each row carries its own $/mg figure, so the size of the gap between vendors is visible, not just the order. Sprays follow the vials, unranked.
The best-documented testing flag goes to the vendor publishing batch-level, third-party certificates. The shipping flag goes to the fastest published delivery from a domestic warehouse. Data is re-checked on a schedule and each row carries its verification date.
About DSIP
Delta Sleep-Inducing Peptide — researched for deep sleep, stress reduction, and cortisol modulation.
DSIP — clinical & mechanistic profile
DSIP is a naturally occurring nonapeptide discovered in 1974 that promotes delta wave sleep, reduces stress, and modulates multiple neurotransmitter systems including GABA and endogenous opioids.
Studied applications
- Promotes delta wave (deep) sleep without sedation
- Reduces sleep latency and nocturnal awakenings
- Modulates cortisol and stress response
- No tolerance or dependence reported
Research constraints & safety notes
- Limited human clinical data
- Very short half-life (~8 minutes)
- Limited stability - degrades quickly
- Research primarily from Soviet-era studies
DSIP is a naturally occurring nonapeptide discovered in 1974 that promotes delta wave sleep, reduces stress, and modulates multiple neurotransmitter systems including GABA and endogenous opioids. It has a molecular formula C35H48N10O15, mass 848.8 Da. Its published amino-acid sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Common synonyms in the literature include Delta Sleep-Inducing Peptide, DSIP nonapeptide, and delta sleep peptide.
What it’s studied for
Investigation of DSIP to date is primarily preclinical, with the majority of citations concentrated in animal models and in-vitro assays rather than randomized controlled human trials. Published work referencing DSIP spans Sleep architecture studies: EEG studies in rabbits, rats, and limited human cohorts show DSIP increases delta wave (slow-wave) sleep duration without suppressing REM sleep. Unlike benzodiazepines, it enhances physiological sleep patterns rather than altering them, Chronic insomnia trials: European clinical studies (primarily 1980s-1990s) in patients with chronic insomnia reported improved sleep onset latency, reduced nocturnal awakenings, and enhanced subjective sleep quality. Schneider-Helmert (1983) reported significant improvements in 15 of 16 patients with psychophysiological insomnia, and Stress and HPA axis: DSIP reduces ACTH and cortisol secretion, suggesting anxiolytic and stress-protective properties. Research in alcohol and opioid withdrawal contexts showed DSIP reduced withdrawal symptom severity and normalized stress hormone levels. Proposed mechanisms in the literature include GABA system enhancement and NMDA receptor interaction. None of this material describes therapeutic outcomes in humans, and No vendor listed here provides dosing guidance for DSIP outside laboratory research.
Related research
For the full mechanistic profile, published references, and constraint notes on DSIP, see the DSIP research page. All references cited on that page are peer-reviewed primary literature.
For research use only. This summary is a research-scientific overview compiled from peer-reviewed sources. It is not medical advice and is not intended for human or veterinary consumption.
Mechanisms of action
- GABA system enhancement
- NMDA receptor interaction
- Endogenous opioid system modulation
- Hypothalamic-pituitary-adrenal axis regulation
Specifications
| Attribute | Value |
|---|---|
| Sequence | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu |
| Molecular weight | 848.8 g/mol |
| Molecular formula | C35H48N10O15 |